171 related articles for article (PubMed ID: 7819100)
1. Primary plasma cell leukaemia.
Dimopoulos MA; Palumbo A; Delasalle KB; Alexanian R
Br J Haematol; 1994 Dec; 88(4):754-9. PubMed ID: 7819100
[TBL] [Abstract][Full Text] [Related]
2. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
[TBL] [Abstract][Full Text] [Related]
3. Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.
Sureda A; Pais JR; Pascual J; Pérez Vaquero MA; Hernando JC
Postgrad Med J; 1992 Jun; 68(800):470-2. PubMed ID: 1437933
[TBL] [Abstract][Full Text] [Related]
4. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
5. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma.
Koskela K; Pelliniemi TT; Lakkala T; Remes K
Bone Marrow Transplant; 1998 Feb; 21(3):305-7. PubMed ID: 9489657
[TBL] [Abstract][Full Text] [Related]
7. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
8. Karyotype in multiple myeloma and plasma cell leukaemia.
Weh HJ; Gutensohn K; Selbach J; Kruse R; Wacker-Backhaus G; Seeger D; Fiedler W; Fett W; Hossfeld DK
Eur J Cancer; 1993; 29A(9):1269-73. PubMed ID: 8343266
[TBL] [Abstract][Full Text] [Related]
9. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
11. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
[TBL] [Abstract][Full Text] [Related]
12. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
13. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Telek B; Méhes L; Batár P; Kiss A; Udvardy M
Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
[TBL] [Abstract][Full Text] [Related]
14. Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
Piccinini L; Artusi T; Bonacorsi G; Arigliano V
Haematologica; 2002 Feb; 87(2):EIM04. PubMed ID: 11836178
[No Abstract] [Full Text] [Related]
15. Plasma cell leukaemia mimicking acute monocytic leukaemia in the course of multiple myeloma.
Eclache V; Lusina D; Lejeune F; Casassus P; Smadja N; Lortholary P
Nouv Rev Fr Hematol (1978); 1993 Aug; 35(4):419-22. PubMed ID: 8414961
[TBL] [Abstract][Full Text] [Related]
16. [IgG-lambda-type multiple myeloma with plasma-cell pericardial effusion and terminal plasma-cell leukemia].
Klug S; Höltermann F; Fritsch H
Dtsch Med Wochenschr; 1992 Jun; 117(23):900-4. PubMed ID: 1597118
[TBL] [Abstract][Full Text] [Related]
17. [Multiple myeloma--new therapeutic perspectives].
Skotnicki AB; Wolska-Smoleń T; Jurczyszyn A
Przegl Lek; 1999; 56 Suppl 1():67-72. PubMed ID: 10494186
[TBL] [Abstract][Full Text] [Related]
18. [Plasma cell leukemia. Study of 6 patients].
Las Heras G; Ribera JM; Abella E; Batlle M; Flores A; Millá F; Feliu E
Sangre (Barc); 1992 Aug; 37(4):255-8. PubMed ID: 1514138
[TBL] [Abstract][Full Text] [Related]
19. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
